Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy's launches five generics in US

This article was originally published in Scrip

Executive Summary

Dr Reddy's Laboratories launched five generic products in the US last month. These are levetiracetam tablets 250mg, 500mg, 750mg and 1000mg, generic versions of UCB's Keppra tablets; omeprazole capsules 40mg, a generic version of AstraZeneca's Prilosec DR; lamotrigine CD chewable tablets 5mg and 25mg and lamotrigine tablets 25mg, 100mg, 150mg and 200mg, generic versions of GlaxoSmithKline's Lamictal; and divalproex capsules and delayed-release pellets 125mg, a generic version of Abbott's Depakote delayed-release capsules. Dr Reddy's has 69 ANDAs, addressing innovator sales of $47 billion, pending at the US FDA.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC032002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel